Vbx-026

Vbx-026 is a cancer vaccine candidate developed by Vaxon Biotech, designed for the treatment of solid tumors in patients expressing the HLA-A24 molecule. This molecule is highly prevalent in Asian populations, particularly in Japan. The vaccine utilizes optimized cryptic peptides to stimulate an immune response against tumor antigens, specifically targeting universal tumor antigens such as HER2. The mechanism involves modulation of both HER2 (Receptor tyrosine-protein kinase erbB-2) and HLA-A24 molecules to enhance T lymphocyte activation and anti-tumor immunity. As of the latest updates, Vbx-026 remains at the discovery or preclinical stage[1][2][3][5].